Pentosan Polysulfate Treatment of Mucopolysaccharidosis Type IIIA Mice
Overall Goal: This study was designed to evaluate the impact of pentosan polysulfate (PPS) treatment on mice with mucopolysaccharidosis (MPS) type IIIA (Sanfilippo A syndrome; OMIM 252900).
Protocol: Three groups of MPS IIIA mice were evaluated: 1-week-old mice treated with subcutaneous (subQ) PPS at 25 mg/kg once weekly for 31 weeks (group 1); 5-month-old mice treated with subQ PPS once weekly at 50 mg/kg for 12 weeks (group 2); and 5-week-old mice treated by continual intracerebroventricular (ICV) PPS infusion for 11 weeks (60 μg/kg/day). Treated MPS IIIA mice and controls were assessed by measuring plasma cytokine levels, histologic analyses of systemic organs, and analyses of various neuroinflammatory, neurodegenerative, and lysosomal disease markers in their brains. Neurobehavioral testing also was carried out.
Results: As seen in other MPS animal models, subQ PPS treatment reduced plasma cytokine levels and macrophage infiltration in systemic tissues. ICV administration did not elicit these systemic effects. SubQ PPS administration also significantly impacted brain neuropathology, inflammation, and behavior. The effect of early subQ treatment was more significant than dose. Surprisingly, ICV PPS treatment had intermediate effects on most of these brain markers, perhaps due to the limited dose and/or duration of treatment. Consistent with these neuropathological findings, we also observed significant improvements in the hyperactivity/anxiety and learning behaviors of the MPS IIIA mice treated with early subQ PPS.
KeywordsCentral nervous system Mucopolysaccharidosis type IIIA Neuroinflammation Pentosan polysulfate
Blood brain barrier
Bovine serum albumin
Central nervous system
Cerebral spinal fluid
Enzyme-linked immunosorbent assays
Granulocyte colony stimulating factor
Glial fibrillary acidic protein
Hematopoietic stem cell transplantation
Lysosomal integral membrane protein-2
Lysosomal storage disorder
Monocyte chemoattractant protein-1
Macrophage inflammatory protein-1 alpha
Phosphate buffered saline
The research was funded by the Stop Sanfilippo Foundation.
- Greenslade D, Ward J, Hopkins R (1983) (3H)-sodium pentosan polysulfate (SP 54): a study of the elimination of radioactivity following subcutaneous administration to the rat. Report No. 3484-218/5, Hazleton Laboratories EuropeGoogle Scholar
- Hennermann JB, Gökce S, Solyom A, Mengel E, Schuchman EH, Simonaro CM (2016) Treatment with pentosan polysulphate in patients with MPS I: results from an open label, randomized, monocentric phase II study. J Inherit Metab Dis 39(6):831–837. https://doi.org/10.1016/j.bbacli.2017.02.001 CrossRefPubMedGoogle Scholar
- Herrero LJ, Foo SS, Sheng KC, Chen W, Forwood MR, Bucala R et al (2015) Pentosan polysulfate: a novel glycosaminoglycan-like molecule for effective treatment of alphavirus-induced cartilage destruction and inflammatory disease. J Virol 89(15):8063–8076. https://doi.org/10.1128/JVI.00224-15 CrossRefPubMedPubMedCentralGoogle Scholar